Evidence map›Paper›PMID 38694257›Full record

ReviewFrontiers in aging neuroscience2024

Clathrin mediated endocytosis in Alzheimer's disease: cell type specific involvement in amyloid beta pathology.

Sierra Jaye, Ursula S Sandau, Julie A Saugstad

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in aging neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. BAG3 modulates clathrin-mediated endocytosis and tau uptake in astrocytes.American journal of physiology. Cell physiology · 2026
    Article
  4. Self-Assembling Short Peptide Carriers for Gene Delivery.International journal of molecular sciences · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Cells · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sierra JayeDepartment of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, OR, United States.
Ursula S SandauDepartment of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, OR, United States.
Julie A SaugstadDepartment of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, OR, United States.
Oregon Health & Science University · US

Funding

Neuroscience of Aging, Neurodegeneration and Alzheimer’s DiseaseT32AG055378 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI JACOB RABER, HENRYK F URBANSKI · 2018 to 2026
$4.3M
Establishing MicroRNA Biomarkers for Diagnosing Alzheimer's Disease & Predicting ProgressionRF1AG059392 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI SAUGSTAD, JULIE ANNE · 2019 to 2019
$3.4M
NIA NIH HHS RF1 AG059392NIA NIH HHS T32 AG055378
6 · The paper itself

Abstract

This review provides a comprehensive examination of the role of clathrin-mediated endocytosis (CME) in Alzheimer's disease (AD) pathogenesis, emphasizing its impact across various cellular contexts beyond neuronal dysfunction. In neurons, dysregulated CME contributes to synaptic dysfunction, amyloid beta (Aβ) processing, and Tau pathology, highlighting its involvement in early AD pathogenesis. Furthermore, CME alterations extend to non-neuronal cell types, including astrocytes and microglia, which play crucial roles in Aβ clearance and neuroinflammation. Dysregulated CME in these cells underscores its broader implications in AD pathophysiology. Despite significant progress, further research is needed to elucidate the precise mechanisms underlying CME dysregulation in AD and its therapeutic implications. Overall, understanding the complex interplay between CME and AD across diverse cell types holds promise for identifying novel therapeutic targets and interventions.

Indexed as

Alzheimer’s diseaseamyloid betaclathrin mediated endocytosisendolysosomal dysfunctiontherapeutics

Identifiers

PMID38694257
PMCPMC11061891
OpenAlexW4394904573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.